Venus Remedies expects organic growth of 15%

22 Jul 2013 Evaluate

Venus Remedies is expecting 15% organic growth while projecting its topline products to grow to Rs 1,000 crore by FY’17 from the current Rs 460 crore in FY’13. The drug maker is expecting this kind of growth on back of higher exports and following R&D share of its revenue increasing from present 33% to 50% as the margins for company’s R&D products are much higher than generic products.

The company currently has 25 products under its research and development portfolio, of which 13 are already commercialized. The company has obtained patent for its Elores antibiotic against Superbugs from Japanese authorities. The product has so far received 46 patents from the developed world. The company has already launched this product in India and plans to launch it in Japan by end of 2015.

Besides, the company also hopes to increase its overall exports share to 50% from the present 31% in US, Canada, Japan, Europe and South Korean markets.

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.

Venus Remedies Share Price

823.10 -2.70 (-0.33%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×